Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Lymphoma, Non-Hodgkin × Nivolumab × Clear all

Phase

Phase 2 4 Phase 1/2 4 Phase 1 4 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 6 Stomach Neoplasms 3 Adenocarcinoma Of Esophagus 3 Carcinoma, Hepatocellular 2 Uveal Melanoma 1 Recurrence 1 Prostatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Muscle Invasive Bladder Urothelial Carcinoma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Hodgkin Disease 1 Hepatitis B 1 Gliosarcoma 1 GATA2 Deficiency 1 Esophageal Squamous Cell Carcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Advanced or Metastatic Solid Malignancies 1 Adenocarcinoma of Lung 1

Interventions

Rituximab 4 Etoposide 4 Whole-Body Irradiation 2 Gemcitabine 2 Cyclophosphamide 2 umbralisib 1 ublituximab 1 rasburicase 1 pegfilgrastim 1 fludarabine phosphate 1 fludarabine 1 epratuzumab 1 aldesleukin 1 Trimethoprim, Sulfamethoxazole Drug Combination 1 Thiotepa 1 Radioimmunodetection 1 Prednisone 1 Oxaliplatin 1 Nivolumab 1 Melphalan 1 Leucovorin 1 Lenalidomide 1 Immunoglobulins, Intravenous 1 Hizentra 1 Filgrastim 1 Doxorubicin 1 Cytarabine 1 Ciprofloxacin 1 Carboplatin 1 Busulfan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03366272 2025-01-28

NIVEAU

Universität des Saarlandes

Phase 2/3 Completed

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡